INTRODUCTION

The Department of Haematology provides clinical and laboratory haematology services for the southern sector of the South Eastern Sydney Local Health District.

The clinical unit provides comprehensive care to patients with a broad spectrum of benign and malignant haematological disorders including anaemias, leukaemias, lymphomas, myelomas and disorders of haemostasis or thrombosis.

The unit also provides high dose therapy and autologous stem cell transplantation. Our haematologists manage both general haematological and haemato-oncological conditions.

The Department of Haematology is accredited by the Royal College of Pathologists of Australasia for supervised registrar training in Haematology, and actively participates in training junior laboratory staff. The Department is a centre of excellence catering for the diagnostic, clinical, research and teaching activities of the SESLHD.

Clinical Excellence - Research Excellence - Laboratory Excellence

Principal Investigators are supported by a team of physicians, scientists and research staff dedicated to laboratory and clinical research.

The SEALS Haematology Laboratory is NATA AS4633 (ISO 15189) and AS/NZS ISO 9001:2000 accredited and provides a range of laboratory services in haematology including automated blood cell analysis and morphology, bone marrow examination, flow cytometry, routine and special coagulation assays, transfusion medicine and haemopoietic stem cell transplantation. An area reference services is provided for B12 and folate assays, intrinsic factor antibodies, whole blood aggregation and heparin induced anti-platelet antibodies. A state wide reference service is provided for drug-dependent and autoimmune anti-platelet antibodies.

The Clinical Trials Unit (CTU) has been operating since July 1993. The Unit is co-located in a dedicated trial unit space alongside the Cancer Care Centre in the W R Pitney Building. The unit has a staff of clinical research co-ordinators and research nurses reporting to a clinical trials unit manager. We operate from two purpose-built clinical trials units over two hospitals. In 2007, the Centre for Thrombotic and Bleeding Disorders Research was formed, delivering investigator-led research primarily into VTE and ITP. In 2011, an International ITP registry was set up with St George Hospital as the co-ordinating centre for potentially hundreds of research sites worldwide.

The Haematology Research Laboratory (Department of Medicine) operates from the St George Research Building, and within the SEALS complex of laboratories. The Basic and Translational Research Laboratory in the St George Clinical School has a history of excellence, publishing original research in high impact international science/medical journals such as Science Translational Medicine, BLOOD, Molecular and Cellular Biology,
New England Medical Journal, Lancet, and Cancer Research. The Haematology Research Laboratory is and has been funded by Category 1 grants including NHMRC project/program grants (continuously since 1990; 4 renewals of NHMRC Program grants), ARC, NHF, Commonwealth AIDS Research grant and international grants including Singapore National Medical Research Council grant.

SEALS laboratories maintain laboratory services, which includes laboratory research activities.

Both St George Hospital and Sutherland Hospital facilities are ideally positioned for conducting research utilising both inpatient and outpatient based populations.

**Our Mission Statement:**

*Making a difference in Healthcare through quality research*

All clinical research is conducted in accordance with the:

*NHMRC National Statement on Ethical Conduct in Human Research*
The Haematology Department at St George and Sutherland Hospitals has an extensive record of research, and this report demonstrates the depth of research for the last 10 years. Programs encompass basic science, cardiovascular disorders and translational research with a focus on platelets; through to the clinical research unit, which has grown dramatically in the last 10 years.

It takes a team to produce good research results, and I am proud of our contributions to the scientific community, and recommend this report to you.

Professor Beng Hock Chong.
TABLE OF CONTENTS

INTRODUCTION .......................................................................................................................... i
FROM THE DIRECTOR OF HAEMATOLOGY .............................................................................. iii
TABLE OF CONTENTS ................................................................................................................ iv
ST GEORGE/SUTHERLAND HOSPITALS AND HEALTH SERVICES ............................................. 1
HAEMATOLOGY ORGANISATIONAL STRUCTURE ..................................................................... 2
HAEMATOLOGISTS AND RESEARCH INTEREST ....................................................................... 3
RESEARCH AREAS .................................................................................................................... 8
   CENTRE FOR THROMBOTIC AND BLEEDING DISORDERS RESEARCH ..................................... 8
   INITIATION OF CTBR ITP INTERNATIONAL REGISTRY 2011 .................................................. 10
   HAEMATOLOGY CLINICAL TRIALS UNIT ............................................................................... 12
   HAEMATOLOGY TRIALS 1997-2011 ..................................................................................... 13
   SEALS LABORATORY ACTIVITIES ..................................................................................... 27
   BASIC AND TRANSLATIONAL RESEARCH LABORATORY (St George Clinical School) .............. 28
RESEARCH GRANTS ............................................................................................................... 33
   COMMERCIAL FUNDING – CURRENTLY HELD BH CHONG .................................................. 37
PUBLICATIONS ..................................................................................................................... 39
   BH CHONG ......................................................................................................................... 39
   SH LEE ............................................................................................................................... 46
   S RAMANATHAN ............................................................................................................... 48
   SJ HO ................................................................................................................................. 48
   F RONCOLATO .................................................................................................................. 49
   X BADOUX ......................................................................................................................... 50
   P CHOI .............................................................................................................................. 51
   N CHAPMAN ..................................................................................................................... 51
   C HICKS .......................................................................................................................... 51
   R WONG ......................................................................................................................... 52
PRESENTATIONS: SCIENTIFIC MEETINGS AND CONFERENCES ................................................... .... 55

BH CHONG .................................................................................................................... 55
SJ HO .............................................................................................................................. 59
X BADOUX ..................................................................................................................... 61
P CHOI .......................................................................................................................... 62
N CHAPMAN ................................................................................................................ 63
R RISTUCCIA ................................................................................................................ 63
C HICKS ......................................................................................................................... 63
S SMITH ......................................................................................................................... 64
R WONG ....................................................................................................................... 65
R GEMMELL .................................................................................................................... 65
J PERDOMO .................................................................................................................... 66

COMMUNITY ENGAGEMENT ....................................................................................... 68
St George Hospital


Sutherland Hospital

HAEMATOLOGY ORGANISATIONAL STRUCTURE

DEPARTMENT OF HAEMATOLOGY STRUCTURE

DIRECTOR: Beng Chong

Medical Teams

Professor Beng Hock Chong

Dr Sunda Ramanathan (Staff Specialist)

Dr Fernando Roncolato (Staff Specialist)

Dr Xavier Badoue (Staff Specialist)

Dr Shir-jing Ho (Staff Specialist)

Dr Amanda Hugman (Staff Specialist)

Professor Szu-Hee Lee

Nursing

Cancer Care Centre (NUR: Lucy Burns)

4N Haematology Ward (NUR: Jennifer Rickard)

Clinical Nurse Consultants (Haematology: Nicole Goodman)

Clinical Nurse Consultants (Cancer Outreach: Cassandra Hobbs / Jo Cryer)

Nurse Educator (Cancer Services: Patricia Morris)

Research

Centre for Thrombotic and Bleeding Disorders Research / Clinical Trials Unit (Manager: Roslyn Ristuccia)

Basic and Translational Research Laboratory (Manager: Dr Jose Perdomo)

SEALS Laboratories Research

Laboratory Services

SEALS Haematology Laboratory (Manager: Sudha Pillai)

B12 / Folate (Senior Technical Officer: Karen Staff)

Flow Cytology (Senior Hospital Scientist: Susan Smith)

Blood Bank (Senior Hospital Scientist: Peter Laizou)

Main Laboratory (Technical Officer: Reina Nair)

Bone Marrow Transplant Laboratory (Senior Hospital Scientist: Christine Wasse)

Morphology (Senior Hospital Scientist: Nella Mangos and Nicole Lawes)

Coagulation / Special Coagulation (Senior Hospital Scientist: Rosalie Gammel)

Transfusion (Governance Coordinator: Patricia Pillai)
Director of Haematology:

Professor Beng Chong, MBBS, PhD (Syd), FRCP (Glasgow), FRACP, FRCPA

Professor (Conjoint), Department of Medicine, St George Clinical School, University of New South Wales (UNSW).
Director, Clinical and Laboratory Haematology, St George and Sutherland Hospitals and SEALS Central.
Member, UNSW Research Management Committee, Faculty of Medicine

The St George Hospital,
Gray Street KOGARAH NSW 2217
AUSTRALIA
Sec: (612) 9113 2960
Fax: (612) 9113 3426
Email add: beng.chong@unsw.edu.au

His research ranges from basic science to translational and clinical research. Basic research includes transcription regulation of platelet production and megakaryopoiesis, biology of Oncogenes: Fli-1, GATA-1, PU-1 and FOG-1 and stem cell biology. Translational Research includes mechanisms of and novel treatments for immune thrombocytopenias. Clinical research includes prophylaxis and the treatment of venous thromboembolism and Immune thrombocytopenia.

Member of the Board of St George Medical research Foundation and Deputy Chair, Scientific Advisory Committee, St George Medical research Foundation 2007-2012
NHMRC Project Grant assessment panel member 2008 and 2010
Member, Medical and Dental Appointments Advisory Committee, St George Hospital, Sydney since 2001
Member of Clinical Council, St George Hospital, Sydney
Co-chair, Platelet Immunology, International Society of Thrombosis and Haemostasis
Vice-President, Australian Bid Committee, International Society of Thrombosis and Haemostasis, (ISTH) and ISTH Congress 2019
Director, Centre for Thrombosis and Bleeding Disorders research
Chair of Steering committee, International ITP Registry

For more information visit:
http://med.unsw.edu.au/people/professor-beng-chong
**Senior Medical Staff:**

*Professor Szu-Hee Lee, MBBChir, PhD, FRCPE, FRCPA, FRCPA*

Senior Staff Specialist
Haematology Department
The St George Hospital
Gray Street KOGARAH NSW 2217
AUSTRALIA
Phone: (612) 9113 3427
Fax: (612) 9113 3942
Email: Szu-Hee.Lee@sesiahs.health.nsw.gov.au

Dr Lee is Senior Staff Specialist in Haematology at St George Hospital and Conjoint Professor, School of Medical Sciences, University of New South Wales. Dr Lee supervises the diagnostic morphology and transfusion services. His research interests are in laboratory and experimental haematology.

**Staff Specialists:**

*Dr Sundra Ramanathan, MBBS, FRACP, FRCPA*

Staff Specialist Haematology
Haematology Department, The St George Hospital
Gray Street KOGARAH NSW 2217
AUSTRALIA
Phone: (612) 9113 2692 (Secretary: Claire Gore)
Fax: (612) 9113 3958
Email address: Sundra.Ramanathan@sesiahs.health.nsw.gov.au

Dr Ramanathan has an interest in haematological malignancies and is Medical Director of the Bone Marrow Transplant Unit at St George Hospital. He is a Conjoint Lecturer with the University of New South Wales.
Dr Shir-jing Ho, MBBS, FRACP, FRCPA

Staff Specialist Haematology
Haematology Department
Cancer Care Centre, The St George Hospital
Gray Street KOGARAH NSW 2217
AUSTRALIA
Phone: (612) 9113 3425
Fax: (612) 9113 3942
Email: shir-jing.ho@sesiahs.health.nsw.gov.au

Dr Ho’s clinical research includes treatment of acute and chronic leukaemias and lymphoma, as well as problems of thrombosis and haemostasis. She has a laboratory interest in haemostasis and platelet disorders.

Dr Fernando Roncolato, B Med FRACP FRCPA

Staff Specialist Haematology
Department of Haematology
Cancer Care Centre, The St George Hospital
Gray Street KOGARAH NSW 2217
AUSTRALIA
Phone: (612) 9113 3851
Fax: (612) 9113 3958
Email add: Fernando.Roncolato@sesiahs.health.nsw.gov.au

Dr Roncolato has an interest in the management of lymphoproliferative disorders. He is a Conjoint Lecturer in Medicine at the University of New South Wales. Dr Roncolato undertook research in 2010/2011 at the Department of Haematopathology, University of Bologna, Italy, examining the role of T-cell receptor gene rearrangement analysis in the diagnosis of T-cell lymphomas.

Dr Amanda Hugman, MBBS, FRACP, FRCPA, MPhil

Staff Specialist Haematology
Haematology Department
Cancer Care Centre, The St George Hospital
Gray Street KOGARAH NSW 2217
AUSTRALIA
Phone: (61-2) 9113 3851
Fax: (61-2) 9113 3942
Email add: Amanda.Hugman@sesiahs.health.nsw.gov.au

Dr Hugman has an interest in the management of malignant haematology and general haematology, including iron disorders, thrombosis and haemostasis. She has laboratory research experience in molecular aberrations in acute myeloid leukemias.
Dr Xavier Badoux, MBBS, FRACP, FRCPA

Senior Staff Specialist Haematology
Haematology Department
Cancer Care Centre, The St George Hospital
Gray Street KOGARAH NSW 2217
AUSTRALIA
Phone: (612) 9113 3851
Fax: (612) 9113 3942
Email: Xavier.Badoux@sesiahs.health.nsw.gov.au

Dr Badoux is a clinical haematologist with a research interest in the treatment of lymphoproliferative disorders. He is currently performing translational research in chronic lymphocytic leukemia utilizing next-generation sequencing to identify recurrent mutations in CLL. Dr Badoux is a Conjoint Lecturer in Medicine at the University of New South Wales.

Research Staff:

Senior research staff
Post –doctoral Scientists: José Perdomo, Feng Yan, Xing-Mai Jiang, Jim Fang
Research scientist: Zohra Ahmedi.

Scientific Staff:

Haematology Laboratory
Manager: Sudha Pillai; Deputy Manager: Susan Smith

Chief Scientists:

Laboratory Manager and Quality Representative: Sudha Pillai, BAppSc(Biomedical), MHA, AIMS
Senior Hospital Scientist Blood Bank: Peter Loizou, Path Tech Certificate, BAppSc (Biomedical)
Senior Hospital Scientist Flow Cytometry: Susan Smith, BAppSc (Biomedical)
Senior Hospital Scientist Coagulation and Special Coagulation: Rosalie Gemmell, BAppSc (Clinical Biochemistry)
Senior Hospital Scientist Bone Marrow Transplant Lab: Dr. Christine Wassell, BSc, MSc, PhD
Senior Technical Officer B12/Folate: Karen Staff, Path Techniques, Associate Diploma
Senior Hospital Scientist in charge, Morphology: Nella Mangos, BAppSc (Biomedical), Nicole Lewis, BSc, MPH
**Clinical Trials Unit**

**Clinical Trials Unit Manager**

Roslyn Ristuccia BSc DipCompSc MMEdSc(ClinEpi)

Roslyn was the first research co-ordinator in Haematology clinical trials unit, starting in 1997, and has overseen the growth and quality improvements since then. She has interests in epidemiology, the use of technology in clinical research, and in quality management.

**Clinical Trials Unit - Research Coordinators**

Karina Chui RN (Research Nurse)

In 2001, Karina specialised in Haematology Oncology Nursing at St George Hospital. By 2008, Karina joined the research unit undertaking Malignant Haematology research studies. She currently manages and coordinates multiple Haematology malignant studies such as Myelodysplastic Syndrome, Non Hodgkin’s Lymphoma, Chronic Lymphocytic Lymphoma as well as Polycytemia Vera/Essential Thrombocytethemia.

Sarah Davidson RN (Research Nurse)

Sarah trained as a Registered Nurse at Sydney University. Sarah began her research experience managing sponsored thrombosis trials, after which she moved into both sponsored and collaborative group malignant haematology studies, specifically coordinating CML, lymphoma and myeloproliferative disorder studies. Sarah is currently the Project Manager at the Coordinating Centre for an investigator driven global ITP Registry.

Lorraine King RN (Research Nurse)

Lorraine worked as a Research Nurse for the University of New South Wales School of Medicine before joining the Clinical Research Unit based at Sutherland Hospital in 2008. Lorraine managed research studies in DVT prophylaxis post hip and knee surgery, and then transferred to St George Hospital to work on a variety of malignant Haematology disease registries and clinical trials on Mantle Cell Lymphoma, and CML.

Margaret Loizou BSc (Clinical Research Co-ordinator)

Margaret is an experienced Scientific Officer who joined the trials unit in 2004. Margaret has predominantly managed and coordinated research studies in DVT and ITP. She also has research experience in malignant haematology research studies which includes: Multiple Myeloma, Chronic Lymphocytic Leukaemia, Polycytemia Vera/Essential Thrombocytethemia.

Elena Simon Mendoza BMEdSc (Clinical Research Co-ordinator)

Before joining the research unit in Aug 2009 Elena worked as a scientific officer for 4 years in the department of Seals Pathology. Elena co-ordinates research studies in Venous Thromboembolism, as well as studies specialising in Heparin Induced Thrombocytopenia and chronic myeloid leukaemia.

Kareen Fierro (Clinical Trials Assistant)

Kareen has been working at the St George Clinical Trials unit since 2009. Kareen is a liaison officer between Ethics, RGO, Investigators and Sponsors.

(Note: These are our present staff as at time of going to press. We also wish to acknowledge the contributions of the many other staff over the last 10 years who have since moved to positions elsewhere.)
RESEARCH AREAS

CENTRE FOR THROMBOTIC AND BLEEDING DISORDERS RESEARCH

Centre for Thrombotic and Bleeding Disorders Research

In 2007 the Centre for Thrombotic and Bleeding Disorders Research Unit UNSW was established within St George by Professor Beng H. Chong.

**Mission:** The Thrombosis and Bleeding Disorders Unit has been established to improve Australian patient care by:

- Conducting cutting edge, well designed research into thrombosis and bleeding disorders including its treatment and the medical management of patients with these conditions
- Disseminating knowledge to patients, clinicians, students and other health care professionals about this specialty.

This Unit is a collaboration between research teams resulting in expertise in basic science, drug development, clinical research, community health, population health and health service research as well as thrombosis and bleeding disorders research and education, thus ensuring research excellence in clinical and translational research.
The following research projects have been carried out.

<table>
<thead>
<tr>
<th>Protocol #</th>
<th>Study title</th>
<th>Student / Staff</th>
<th>Planned Start</th>
<th>Planned finish</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Objective 1:</strong> Improve VTE prophylaxis (Px) in hospitalised patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CTBR 007B</td>
<td>Understanding facilitators, barriers and attitudes to VTE Px</td>
<td>Steve Lazar</td>
<td>Complete 2009</td>
<td>Publish 2010</td>
</tr>
<tr>
<td>CTBR 007C</td>
<td>Understanding when VTE Px is considered or could be considered to improve compliance</td>
<td>Bridget Josephs</td>
<td>Feb 2010</td>
<td>Nov 2010</td>
</tr>
<tr>
<td>CTBR 007D</td>
<td>VTE Prophylaxis in a rural hospital</td>
<td>Bridget Josephs</td>
<td>Complete 2010</td>
<td>Publish 2010</td>
</tr>
<tr>
<td></td>
<td>VTE risk assessment by nursing staff intervention - pilot</td>
<td>Mary Clarke</td>
<td>Nov 2009</td>
<td>July 2010</td>
</tr>
<tr>
<td>CTBR 007A</td>
<td>ACCP guideline validation – pilot study</td>
<td>Nicola Chapman</td>
<td>Jan 2011</td>
<td>Dec 2011</td>
</tr>
<tr>
<td></td>
<td>ACCP guideline validation (pending pilot results and ARC grant)</td>
<td>Nicola Chapman</td>
<td>2011</td>
<td>Dec 2011</td>
</tr>
<tr>
<td>CTBR 011</td>
<td>Testing Interventions to improve VTE Px rates</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Audit of surgical VTE Px implementation</td>
<td>Jocelyn Aitken</td>
<td>August 2010</td>
<td>November 2010</td>
</tr>
<tr>
<td></td>
<td>NSW Health medication chart intervention</td>
<td>Nicola Chapman</td>
<td>August 2010</td>
<td>September 2011</td>
</tr>
<tr>
<td><strong>Objective 2:</strong> Determine if VTE prophylaxis (Px) is indicated in community based patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CTBR-014</td>
<td>Retrospective study VTE incidence of heart failure and respiratory failure in the community</td>
<td>Rima Mourad</td>
<td>Feb 2010</td>
<td>Nov 2010</td>
</tr>
<tr>
<td>CTBR 014A</td>
<td>prospective study of VTE incidence in heart failure patients in the community</td>
<td>Justin Friedman</td>
<td>Feb 2011</td>
<td>Dec 2011</td>
</tr>
<tr>
<td><strong>Objective 3:</strong> Optimise treatment of VTE patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CTBR 001A</td>
<td>A VTE registry</td>
<td>Roslyn Ristuccia</td>
<td>2007</td>
<td>Ongoing</td>
</tr>
<tr>
<td>CTBR 001B</td>
<td>VTE Pattern of Care study</td>
<td>Mary Clarke</td>
<td>2008</td>
<td>Nov 2010</td>
</tr>
<tr>
<td>CTBR 009</td>
<td>Understand facilitators and obstacles to optimal VTE management in the community.</td>
<td>Tbd (awaiting student interest; HREC approved)</td>
<td>Tbd</td>
<td>Tbd</td>
</tr>
<tr>
<td></td>
<td>RCT of clexane vs warfarin for calf clots</td>
<td>Jocelyn Aitken</td>
<td>March 2010</td>
<td>2012</td>
</tr>
<tr>
<td><strong>Objective 5:</strong> Improve treatment of idiopathic thrombocytopenic purpura (ITP).</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CTBR 003</td>
<td>ITP registry</td>
<td>Sarah Davidson/Beng Chong</td>
<td>Q3 2010</td>
<td>2012-2015</td>
</tr>
<tr>
<td></td>
<td>Ginseng for ITP treatment</td>
<td>Roslyn Ristuccia/Beng Chong</td>
<td>2013</td>
<td>2014</td>
</tr>
<tr>
<td><strong>Objective 6:</strong> Identify a treatment for patients with heparin-induced t’penia (HIT)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CTBR 005</td>
<td>Characterisation of HIT antibodies</td>
<td>Sima / Nathalie / Arend / Zohra</td>
<td>Feb 2009</td>
<td>2010</td>
</tr>
<tr>
<td></td>
<td>RCT of lepirudin to fondaparinux</td>
<td>Phil Choi</td>
<td>Tbd</td>
<td>Tbd</td>
</tr>
<tr>
<td><strong>Objective 7:</strong> Drug induced thrombocytopenia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CTBR 008</td>
<td>Vancomycin and thrombocytopenia antibody incidence</td>
<td>Nathalie / Elizabeth</td>
<td>Feb 2009</td>
<td>2010</td>
</tr>
</tbody>
</table>

Department of Haematology Research Report 2001-2011 Version 1
INITIATION OF CTBR ITP INTERNATIONAL REGISTRY 2011

ITP is a bleeding disorder in which the immune system destroys the patient’s own platelets causing depletion of platelets (blood cells involve in blood clot formation and prevent us from bleeding). Without enough platelets, bleeding can occur and it can range from mild bruising to severe and fatal haemorrhage.

In 2011, the Centre for Thrombosis and Bleeding Disorders Research at St George Hospital, initiated an Investigator-led International ITP Registry.

“A Multi-centre, prospective disease registry for adults diagnosed with primary immune thrombocytopenia (ITP) in international countries.”

Professor Beng H. Chong chairs the International Registry Steering Committee which manages this registry. Conducted and data managed from St George Hospital the disease registry has garnered interest from more than 45 haematologists from across the Asia-Pacific, Middle Eastern and South American regions including Australia, Japan, Korea, India, China, Singapore, Turkey, Israel, Brazil.
As at December 2011, the Registry had the following active sites and recruitment:

<table>
<thead>
<tr>
<th>COUNTRY/REGION</th>
<th>SITES ACTIVATED</th>
<th>PATIENTS ENROLLED</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUSTRALIA</td>
<td>3</td>
<td>5 PENDING*</td>
</tr>
<tr>
<td>HONG KONG</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>JAPAN</td>
<td>-</td>
<td>3 PENDING*</td>
</tr>
<tr>
<td>SOUTH KOREA</td>
<td>-</td>
<td>10 PENDING*</td>
</tr>
<tr>
<td>MALAYSIA</td>
<td>4</td>
<td>-</td>
</tr>
<tr>
<td>SINGAPORE</td>
<td>1</td>
<td>2 PENDING*</td>
</tr>
<tr>
<td>TAIWAN</td>
<td>-</td>
<td>10 PENDING*</td>
</tr>
<tr>
<td>THAILAND</td>
<td>5</td>
<td>1 PENDING*</td>
</tr>
<tr>
<td>ALGERIA</td>
<td>1</td>
<td>-</td>
</tr>
<tr>
<td>EGYPT</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>KUWAIT</td>
<td>1</td>
<td>-</td>
</tr>
<tr>
<td>LEBANON</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>MOROCCO</td>
<td>1</td>
<td>-</td>
</tr>
<tr>
<td>PAKISTAN</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>TURKEY</td>
<td>-</td>
<td>8 PENDING*</td>
</tr>
<tr>
<td>ISRAEL</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>LATIN AMERICA</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Growing quickly, it is expected that in 2012 the registry will expand considerably across the world.
**HAEMATOLOGY CLINICAL TRIALS UNIT**

**The Clinical Trials Unit (CTU)** has been operating since July 1993. The Unit is co-located in a dedicated trial unit space alongside the Cancer Care Centre in the W R Pitney Building. The unit has a staff of clinical research co-coordinators and research nurses reporting to a clinical trials unit manager. We operate from two purpose-built clinical trials units over two hospitals.

Both facilities are ideally positioned for conducting research, and utilising both inpatient and outpatient based populations. The St George Clinical School, operating from St George Hospital, is part of the University of New South Wales.

Over the last 10 years, the clinical trials unit has demonstrated huge growth. From 1 part-time staff member running one study, we now have 7 co-ordinators, administration staff, and a portfolio of over 30 active studies.

All aspects of our conduct are governed by quality standards and in compliance with relevant regulations, hospital policy and current best practice.

St George Hospital is a member of the NSW Network of Haematology Clinical Research Sites.

Refer to our websites:

[St George/Sutherland Haematology Clinical Trials Unit](#)

[NSW Network of Haematology Clinical Research Sites](#)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Haematology Trials</td>
<td>11</td>
<td>12</td>
<td>14</td>
<td>24</td>
<td>20</td>
<td>28</td>
<td>28</td>
<td>30</td>
</tr>
</tbody>
</table>

There has been a consistent increase in the number of trials conducted in haematology since its early beginnings. The first studies conducted in haematology were mainly thrombosis and haemostasis studies, contributing to the work done for the approval of the new brands of oral anticoagulants.

The Cancer Institute Grant awarded to Haematology CTU in 2008 to employ an extra clinical research co-ordinator was utilised to increase the number of malignant haematology studies being conducted. This increase has been sustained and improved upon. St George Haematology CTU increased the total number of clinical research trials being conducted to 30 in 2011.
<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Comparison</th>
<th>Intervention</th>
<th>Phase</th>
<th>Sponsor</th>
<th>Recommend</th>
</tr>
</thead>
<tbody>
<tr>
<td>Efficacy and safety of the oral thrombin inhibitor SH-TPU-0002 vs standard therapy (lnfinitum and warfarin) for acute, symptomatic deep vein thrombosis with or without pulmonary embolism. A double-blind, randomized, placebo-controlled, single-center study.</td>
<td>Phase II</td>
<td>SH-TPU-0002 vs Placebo</td>
<td>lnfinitum + Warfarin</td>
<td>III</td>
<td>Shire</td>
<td>Archived</td>
</tr>
<tr>
<td>Trials II</td>
<td>Phase II validation study</td>
<td>A multicentre, double-blind, randomised, placebo-controlled study of fondaparinux sodium (63129) vs placebo for the prevention of deep vein thrombosis in hip fracture surgery.</td>
<td>DPC-906</td>
<td>III</td>
<td>AstraZeneca</td>
<td>Archived</td>
</tr>
<tr>
<td>D-Dimer</td>
<td>Phase II</td>
<td>A phase II, randomised, double-blind, active controlled study (enoxaparin sodium) vs placebo in the prevention of deep vein thrombosis in hip fracture surgery.</td>
<td>DPC-906</td>
<td>III</td>
<td>Abbott</td>
<td>Archived</td>
</tr>
<tr>
<td>Efficacy and safety of the oral thrombin inhibitor SH-TPU-0002 vs standard therapy (lnfinitum and warfarin) for acute, symptomatic deep vein thrombosis with or without pulmonary embolism. A double-blind, randomized, placebo-controlled, single-center study.</td>
<td>Phase II</td>
<td>SH-TPU-0002 vs Placebo</td>
<td>lnfinitum + Warfarin</td>
<td>III</td>
<td>Shire</td>
<td>Archived</td>
</tr>
<tr>
<td>Trials II</td>
<td>Phase II validation study</td>
<td>A multicentre, double-blind, randomised, placebo-controlled study of fondaparinux sodium (63129) vs placebo for the prevention of deep vein thrombosis in hip fracture surgery.</td>
<td>DPC-906</td>
<td>III</td>
<td>AstraZeneca</td>
<td>Archived</td>
</tr>
<tr>
<td>D-Dimer</td>
<td>Phase II</td>
<td>A phase II, randomised, double-blind, active controlled study (enoxaparin sodium) vs placebo in the prevention of deep vein thrombosis in hip fracture surgery.</td>
<td>DPC-906</td>
<td>III</td>
<td>Abbott</td>
<td>Archived</td>
</tr>
<tr>
<td>Efficacy and safety of the oral thrombin inhibitor SH-TPU-0002 vs standard therapy (lnfinitum and warfarin) for acute, symptomatic deep vein thrombosis with or without pulmonary embolism. A double-blind, randomized, placebo-controlled, single-center study.</td>
<td>Phase II</td>
<td>SH-TPU-0002 vs Placebo</td>
<td>lnfinitum + Warfarin</td>
<td>III</td>
<td>Shire</td>
<td>Archived</td>
</tr>
<tr>
<td>Trials II</td>
<td>Phase II validation study</td>
<td>A multicentre, double-blind, randomised, placebo-controlled study of fondaparinux sodium (63129) vs placebo for the prevention of deep vein thrombosis in hip fracture surgery.</td>
<td>DPC-906</td>
<td>III</td>
<td>AstraZeneca</td>
<td>Archived</td>
</tr>
<tr>
<td>D-Dimer</td>
<td>Phase II</td>
<td>A phase II, randomised, double-blind, active controlled study (enoxaparin sodium) vs placebo in the prevention of deep vein thrombosis in hip fracture surgery.</td>
<td>DPC-906</td>
<td>III</td>
<td>Abbott</td>
<td>Archived</td>
</tr>
<tr>
<td>Efficacy and safety of the oral thrombin inhibitor SH-TPU-0002 vs standard therapy (lnfinitum and warfarin) for acute, symptomatic deep vein thrombosis with or without pulmonary embolism. A double-blind, randomized, placebo-controlled, single-center study.</td>
<td>Phase II</td>
<td>SH-TPU-0002 vs Placebo</td>
<td>lnfinitum + Warfarin</td>
<td>III</td>
<td>Shire</td>
<td>Archived</td>
</tr>
<tr>
<td>Trials II</td>
<td>Phase II validation study</td>
<td>A multicentre, double-blind, randomised, placebo-controlled study of fondaparinux sodium (63129) vs placebo for the prevention of deep vein thrombosis in hip fracture surgery.</td>
<td>DPC-906</td>
<td>III</td>
<td>AstraZeneca</td>
<td>Archived</td>
</tr>
<tr>
<td>D-Dimer</td>
<td>Phase II</td>
<td>A phase II, randomised, double-blind, active controlled study (enoxaparin sodium) vs placebo in the prevention of deep vein thrombosis in hip fracture surgery.</td>
<td>DPC-906</td>
<td>III</td>
<td>Abbott</td>
<td>Archived</td>
</tr>
<tr>
<td>Study</td>
<td>Description</td>
<td>Sponsor</td>
<td>Lead Investigator</td>
<td>Phase</td>
<td>Start Date</td>
<td>Status</td>
</tr>
<tr>
<td>-------</td>
<td>-------------</td>
<td>---------</td>
<td>------------------</td>
<td>-------</td>
<td>------------</td>
<td>--------</td>
</tr>
<tr>
<td><strong>Exclaim-St George</strong></td>
<td>A Double-Blind, Placebo-Controlled, Parallel, Multicenter Study on Extended VTE Prophylaxis in Acutely III Medical Patients with Prolonged Immobilisation</td>
<td>XRP456 3C/3501 Aventis</td>
<td>Tim Brighton / Beng Hock Chong</td>
<td>Phase III</td>
<td>01-Nov-2002</td>
<td>Archived</td>
</tr>
<tr>
<td><strong>TEMPEST</strong></td>
<td>Thromboembolism Prevention Efficacy and Safety Trial (TEMPEST): A Double-blind Four-week Study to Assess the Efficacy, Safety, and Tolerability of SB 424323 in the Extended Prophylaxis of patients Following Total Hip Arthroplasty</td>
<td>424323/ 025 GlaxoSmithKline</td>
<td>Tim Brighton / Beng Hock Chong</td>
<td>Phase II</td>
<td>01-Dec-2002</td>
<td>Archived</td>
</tr>
<tr>
<td><strong>ALLG MM6</strong></td>
<td>A multicentre randomised phase III study of low-dose thalidomide, prednisolone and zolendronic acid versus prednisolone and zolendronic acid for post-asct maintenance therapy in patients with multiple myeloma.</td>
<td>MM6 ALLG Kiran Phadke</td>
<td></td>
<td>Phase III</td>
<td>01-Apr-2003</td>
<td>Closed-No Participants</td>
</tr>
<tr>
<td><strong>ASPIRE</strong></td>
<td>Aspirin to prevent recurrent venous thromboembolism. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial oral anticoagulation to prevent recurrent venous thromboembolism.</td>
<td>ASPIRE NHMRC-CTC Beng Hock Chong</td>
<td></td>
<td>Phase III</td>
<td>05-May-2005</td>
<td>Closed-No Participants</td>
</tr>
<tr>
<td><strong>PROVE</strong></td>
<td>A Prospective Registry On Venous Thromboembolic Events</td>
<td>Aventis</td>
<td>Tim Brighton</td>
<td></td>
<td>12-May-2005</td>
<td>Archived</td>
</tr>
<tr>
<td><strong>Troxacitine</strong></td>
<td>A phase III randomised, multi-centre study of troxacitine alone, troxacitine in combination with cytarabine or high-dose cytarabine alone in patients with acute myeloid leukaemia in first relapse Protocol Number SPD758-301</td>
<td>SPD758-301 Shire Pharmaceutical</td>
<td>Tim Brighton</td>
<td>Phase III</td>
<td>26-May-2005</td>
<td>Archived</td>
</tr>
<tr>
<td><strong>VanGogh DVT</strong></td>
<td>The Van Gogh-DVT Trial, a multicenter, international, randomised, open-label, assessor-blinded, non-inferiority study comparing the efficacy and safety of once-weekly subcutaneous SanOrg 34006 with the combination of (LMW)Heparin and vitamin K antagonist in the treatment of acute Deep Vein Thrombosis</td>
<td>EFC3491/54717 Sanofi Synelabo</td>
<td>Tim Brighton / Beng Hock Chong</td>
<td>Phase III</td>
<td>22-Jul-2003</td>
<td>Archived</td>
</tr>
<tr>
<td>Study</td>
<td>Description</td>
<td>Sponsor</td>
<td>Sponsor</td>
<td>Investigator</td>
<td>Phase</td>
<td>Start Date</td>
</tr>
<tr>
<td>-----------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>------------------------------</td>
<td>---------</td>
<td>--------------</td>
<td>-------</td>
<td>------------</td>
</tr>
<tr>
<td>VanGogh PE</td>
<td>A multicenter, international, randomised, open-label, assessor-blind, non-inferiority study comparing the efficacy and safety of once-weekly subcutaneous SanOrg34006 with the combination of (LMW)Heparin and vitamin K antagonist (VKA) in the treatment of acute symptomatic Pulmonary Embolism</td>
<td>Sanofi Synthelabo</td>
<td>Beng Hock Chong</td>
<td>Phase III</td>
<td>64714/EFC 3484</td>
<td>22-Jul-2003</td>
</tr>
<tr>
<td>Van Gogh Extension</td>
<td>The Van Gogh Extension-study (P64721/EFC 5135), a multicenter, international, randomized, double-blind, study comparing the efficacy and safety of once-weekly subcutaneous SanOrg34006 with placebo in the long-term prevention of symptomatic venous thromboembolism</td>
<td>Sanofi Synthelabo</td>
<td>Beng Hock Chong</td>
<td>Phase III</td>
<td>P64721/EFC 5135</td>
<td>01-Mar-2004</td>
</tr>
<tr>
<td>Prodigio Glion</td>
<td>A Trial of Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients</td>
<td>QCOG</td>
<td>Peter Graham</td>
<td>09-Apr-2004</td>
<td>04/25</td>
<td>Archived</td>
</tr>
<tr>
<td>ODIXa-DVT/11223-DV Study</td>
<td>Oral Direct factor Xa Inhibitor BAY 59-7939 in Patients with acute symptomatic deep vein thrombosis. ODIXa-DVT. A phase II Dose Finding and Proof of Principle Trial</td>
<td>Bayer</td>
<td>Beng Hock Chong</td>
<td>Phase II</td>
<td>11223</td>
<td>01-Jul-2004</td>
</tr>
<tr>
<td>Renovate</td>
<td>A Phase III randomised, parallel group, double-blind, active controlled study to investigate the efficacy and safety of two different dose regimens of orally administered dabigatran etexilate capsules (150 or 220 mg) once daily starting with half dose (i.e.</td>
<td>Boehringer Ingelheim</td>
<td>Beng Hock Chong</td>
<td>Phase III</td>
<td>BI 1160.48</td>
<td>01-Mar-2005</td>
</tr>
<tr>
<td>Study</td>
<td>Description</td>
<td>Code</td>
<td>Sponsor</td>
<td>Principal Investigator</td>
<td>Phase</td>
<td>Start Date</td>
</tr>
<tr>
<td>-------</td>
<td>-------------</td>
<td>------</td>
<td>---------</td>
<td>------------------------</td>
<td>-------</td>
<td>------------</td>
</tr>
<tr>
<td>Re-Model</td>
<td>A Phase III randomised, parallel group, double-blind, active controlled study to investigate the efficacy and safety of two different dose regimens of orally administered dabigatran etexilate capsules [150 or 220 mg once daily starting with half dose (i.e. 116.025 mg)]</td>
<td>1160.25</td>
<td>Boehringer Ingelheim</td>
<td>Beng Hock Chong</td>
<td>Phase III</td>
<td>01-Mar-2005</td>
</tr>
<tr>
<td>NHL16 PRIMA</td>
<td>A multi-centre, phase III, open-label, randomized study in patients with advanced follicular lymphoma evaluating the benefit of maintenance therapy with Rituximab (MabThera) after induction of response with chemotherapy plus Rituximab in comparison with</td>
<td>MO 18264</td>
<td>ALLG</td>
<td>Yiu Lam Kwan</td>
<td>Phase III</td>
<td>01-Nov-2005</td>
</tr>
<tr>
<td>ITP GSK</td>
<td>A double-blind, randomized, placebo-controlled, parallel group study to investigate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of SB-497115-GR, a thrombopoietin receptor agonist, administered at 30, 50 and 75 mg as oral tablet</td>
<td>TRA100 773</td>
<td>GlaxoSmithKline</td>
<td>Beng Hock Chong</td>
<td>Phase II</td>
<td>28-Feb-2006</td>
</tr>
<tr>
<td>Botticelli - STG</td>
<td>Protocol CV185017: A Phase 2 Randomized, Parallel-Arm Study of Oral Direct Factor Xa-Inhibitor Apixaban and Low Molecular Weight Heparin or Fondaparinux With a Vitamin K Antagonist in Subjects With Acute Symptomatic Deep-Vein Thrombosis [CV185-017]. (05/17)</td>
<td>CV1850 17</td>
<td>Bristol-Myers Squibb</td>
<td>Beng Hock Chong</td>
<td>Phase II</td>
<td>28-Feb-2006</td>
</tr>
<tr>
<td>RECORD1</td>
<td>RECORD 1 Study: Regulation of Coagulation in Orthopaedic Surgery to prevent DVT and PE, controlled, double-blind, randomized study of BAY 59-7939 in the extended prevention of VTE in patients undergoing elective total hip replacement.</td>
<td>11354</td>
<td>Bayer</td>
<td>Beng Hock Chong</td>
<td>Phase II</td>
<td>07-Jun-2006</td>
</tr>
<tr>
<td>Study Name</td>
<td>Description</td>
<td>Sponsor(s)</td>
<td>Investigator(s)</td>
<td>Phase</td>
<td>Study Start Date</td>
<td>Study Status</td>
</tr>
<tr>
<td>----------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>--------------------</td>
<td>-----------------</td>
<td>-------</td>
<td>------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Botticelli - TSH</td>
<td>A Phase 2 Randomized, Parallel-Arm Study of Oral Direct Factor Xa-Inhibitor Apixaban and Low Molecular Weight Heparin or Fondaparinux With a Vitamin K Antagonist in Subjects With Acute Symptomatic Deep Vein Thrombosis (CV1850-017).</td>
<td>Bristol-Myers Squibb, Beng Hock Chong</td>
<td></td>
<td>Phase II</td>
<td>07-Jul-2006</td>
<td>Archived</td>
</tr>
<tr>
<td>EQUINOX - DVT</td>
<td>International, multicenter, randomized, parallel group, double-blind study, in patients with acute symptomatic deep vein thrombosis of the lower limbs, demonstrating the bioequivalence at steady state of equimolar doses of SSR126517E (3.0mg) once a week.</td>
<td>Sanofi-Aventis, Beng Hock Chong</td>
<td></td>
<td>Phase II</td>
<td>28-Jul-2006</td>
<td>Archived</td>
</tr>
<tr>
<td>Pfizer Knee</td>
<td>A Phase 2B, randomised, multicenter, dose-ranging study assessing the safety and efficacy of PD 0348292 in the prevention of venous thromboembolic events (VTE) in subjects undergoing an elective, unilateral total knee replacement</td>
<td>Pfizer, Beng Hock Chong</td>
<td></td>
<td>Phase II</td>
<td>01-Aug-2006</td>
<td>Archived</td>
</tr>
<tr>
<td>ITP EXTEND</td>
<td>(Eltrombopag eXTENded Dosing Study): An extension study of eltrombopag olamine (SB-497115-G1) in adults, with idiopathic thrombocytopenic purpura (ITP), previously enrolled in an eltrombopag study.</td>
<td>GSK, Beng Hock Chong</td>
<td></td>
<td>Phase III</td>
<td>01-Jan-2007</td>
<td>Active-In Follow-up</td>
</tr>
<tr>
<td>ITP REPEAT</td>
<td>An Open-label repeat dosing study of eltrombopag olamine (SB-497115-G1) in adult subjects, with chronic idiopathic thrombocytopenic purpura (ITP): REPEAT (Repeated ExPosure To Eltrombopag in Adults with Idiopathic Thrombocytopenic Purpura)</td>
<td>GSK, Beng Hock Chong</td>
<td></td>
<td>Phase III</td>
<td>02-Feb-2007</td>
<td>Archived</td>
</tr>
<tr>
<td>Apixiban Knee - CV 185 034</td>
<td>A Phase 3 Randomized, Double-Blind, Active-controlled (Enoxaparin), Parallel-Group, Multi-Centre Study to Evaluate the Safety and Efficacy of Oral Apixaban in Subjects Undergoing Elective Total Knee Replacement Surgery</td>
<td>Bristol-Myers Squibb, Beng Hock Chong</td>
<td></td>
<td>Phase III</td>
<td>01-Apr-2007</td>
<td>Archived</td>
</tr>
<tr>
<td>Study</td>
<td>Description</td>
<td>Sponsor</td>
<td>Investigator</td>
<td>Phase</td>
<td>Date</td>
<td>Status</td>
</tr>
<tr>
<td>-------</td>
<td>-------------</td>
<td>---------</td>
<td>--------------</td>
<td>-------</td>
<td>------------</td>
<td>------------</td>
</tr>
<tr>
<td>Apixiban Hip - CV185-035</td>
<td>A Phase 3 Randomized, Double-Blind, Active-controlled, Parallel-group, Multi-centre Study to Evaluate the Safety and Efficacy of Apixaban in Subjects Undergoing Elective Total Hip Replacement Surgery.</td>
<td>CV1850 Bristol-Myers Squibb</td>
<td>Beng Hock Chong</td>
<td>Phase III</td>
<td>01-May-2007</td>
<td>Archived</td>
</tr>
<tr>
<td>ITP LENS</td>
<td>Long term eltrombopag observational study- A long term observational ocular safety follow-up study on adults who have received study medication (SB-497115-GR/eltrombopag olamine or placebo) in a Phase II or phase III clinical study evaluating eltrombopag.</td>
<td>108 132 GSK</td>
<td>Beng Hock Chong</td>
<td>N/A</td>
<td>01-May-2007</td>
<td>Closed-No Participants</td>
</tr>
<tr>
<td>Protalex ITP</td>
<td>PRTX-100A-201, Phase I, An open-label, sequential, dose escalation, repeat-dose study of the safety, pharmacokinetics, pharmacodynamics and immunogenicity of PRTX-100 in adult patients with chronic idiopathic Thrombocytopenic Purpura (ITP)</td>
<td>PRTX-100A-201 Protalex</td>
<td>Beng Hock Chong</td>
<td>Phase I</td>
<td>03-May-2007</td>
<td>Archived</td>
</tr>
<tr>
<td>The EINSTEIN VTE treatment study (St George Hospital)</td>
<td>Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism. The Einstein VTE study</td>
<td>11702 Bayer</td>
<td>Beng Hock Chong</td>
<td>Phase III</td>
<td>09-May-2007</td>
<td>Archived</td>
</tr>
<tr>
<td>The EINSTEIN VTE treatment study</td>
<td>Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism. The Einstein VTE study</td>
<td>11702 Bayer</td>
<td>Beng Hock Chong</td>
<td>Phase III</td>
<td>09-May-2007</td>
<td>Archived</td>
</tr>
<tr>
<td>Cassiopea-STG</td>
<td>An international, multicentre, randomised, double-blind, double-dummy, parallel group, study of 3-month or 6-month treatment with SSR126517E (3.0 mg s.c. once weekly) versus oral INR adjusted warfarin in the treatment of patients with symptomatic pulmonary embolism</td>
<td>EPC6034 Sanofi-Aventis</td>
<td>Beng Hock Chong</td>
<td>Phase III</td>
<td>14-May-2007</td>
<td>Archived</td>
</tr>
<tr>
<td>Study Name</td>
<td>Details</td>
<td>Sponsor</td>
<td>Investigator</td>
<td>Phase</td>
<td>Date</td>
<td>Status</td>
</tr>
<tr>
<td>------------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>---------------</td>
<td>--------------</td>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Cassiopea-TSH</td>
<td>An international, multicentre, randomised, double-blind, double-dummy, parallel group, study of 3-month or 6-month treatment with EFC8034 (3.0 mg s.c. once weekly) versus oral INR adjusted warfarin in the treatment of patients with symptomatic pulmonary embolism.</td>
<td>Sanofi-Aventis</td>
<td>Beng Hock Chong</td>
<td>III</td>
<td>28-May-2007</td>
<td>Archived</td>
</tr>
<tr>
<td>EINSTEIN Ext - 11899 - TSH</td>
<td>Once-daily oral direct factor Xa inhibitor rivaroxaban in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism.</td>
<td>Bayer</td>
<td>Beng Hock Chong</td>
<td>III</td>
<td>01-Jun-2007</td>
<td>Archived</td>
</tr>
<tr>
<td>EINSTEIN Ext - 11899 - STG</td>
<td>Once-daily oral direct factor Xa inhibitor rivaroxaban in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism.</td>
<td>Bayer</td>
<td>Beng Hock Chong</td>
<td>III</td>
<td>01-Jun-2007</td>
<td>Archived</td>
</tr>
<tr>
<td>VTE Sanofi Audit</td>
<td>Venous Thromboembolism (VTE) Taskforce Audit [DIREG_L_01927]</td>
<td>Sanofi-Aventis</td>
<td>Beng Hock Chong</td>
<td>III</td>
<td>01-Jun-2007</td>
<td>Archived</td>
</tr>
<tr>
<td>CSLCT-ITP-05-21</td>
<td>A single-arm, open-label, multi-centre study evaluating the efficacy and safety of Ig NextGen 10% in patients with idiopathic thrombocytopenic purpura (ITP) Protocol CSLCT-ITP-05-21.</td>
<td>CSL</td>
<td>Beng Hock Chong</td>
<td>III</td>
<td>01-Jul-2007</td>
<td>Closed-No Participants</td>
</tr>
<tr>
<td>A Randomized, Controlled, Open-label Study evaluating the Efficacy and Tolerability of AMG531 versus Medical Standard of Care as Chronic Therapy for Non-splenectomized Subjects with immune (Idiopathic) Thrombocytopenia</td>
<td>Amgen</td>
<td>Beng Hock Chong</td>
<td>III</td>
<td>01-Aug-2007</td>
<td>Archived</td>
<td></td>
</tr>
<tr>
<td>MAGELLAN 12839</td>
<td>MAGELLAN – Multicenter, randomized, parallel Group Efficacy and safety study for the prevention of venous thromboembolism in hospitalized medically ill patients comparing rivaroxaban with enoxaparin</td>
<td>Bayer</td>
<td>Beng Hock Chong</td>
<td>07-Jan-2008</td>
<td>Archived</td>
<td></td>
</tr>
<tr>
<td>Study Code</td>
<td>Title</td>
<td>Description</td>
<td>Sponsor</td>
<td>Principal Investigator</td>
<td>End Date</td>
<td>Status/Decision</td>
</tr>
<tr>
<td>------------</td>
<td>----------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------------------------</td>
<td>---------</td>
<td>------------------------</td>
<td>-----------</td>
<td>---------------------</td>
</tr>
<tr>
<td>ALLG TIDEL II CML9</td>
<td>A Phase II study in adult patients with newly diagnosed chronic-phase chronic myeloid leukemia of initial intensified imatinib therapy and sequential dose-escalation followed by treatment with nilotinib in suboptimal responders to determine the rate and duration of major molecular response.</td>
<td>CML9</td>
<td>ALLG</td>
<td>Shir-jing Ho</td>
<td>Phase II</td>
<td>28-Apr-2008</td>
</tr>
<tr>
<td>AMGEN ITP DAN AUDIT 20070190</td>
<td>A Retrospective, Observational Study of Patients with chronic immune (idiopathic) Thrombocytopenic Purpura (ITP) to determine Standard of Care (SOC) in Australia.</td>
<td>20070190</td>
<td>Amgen</td>
<td>Beng Hock Chong</td>
<td>N/A</td>
<td>08-Jul-2008</td>
</tr>
<tr>
<td>CTBR-005 'HIT'S'</td>
<td>Heparin-induced thrombocytopenia (HIT): Characterization of the pathogenic and non-pathogenic antibodies, and studies to improve laboratory diagnosis and treatment.</td>
<td>CTBR HITS</td>
<td>St George Hospital - Haematology</td>
<td>Beng Hock Chong</td>
<td>11-Jul-2008</td>
<td>Active-Recruiting</td>
</tr>
<tr>
<td>AMG 531 Extension 20030213</td>
<td>An Open Label Study Evaluating the Safety and Efficacy of Long-Term Dosing of AMG 531 in Thrombocytopenic Subjects with Immune (Idiopathic) Thrombocytopenic Purpura (ITP)</td>
<td>20030213</td>
<td>Amgen</td>
<td>Beng Hock Chong</td>
<td>Phase III</td>
<td>28-Jul-2008</td>
</tr>
<tr>
<td>ALLG MDS3</td>
<td>A Phase I/II trial to determine safety &amp; efficacy of combination therapy with 5-azacytidine (Vidaza) and Thalidomide in patients with Myelodysplastic Syndromes (MDS)</td>
<td>MD53</td>
<td>ALLG</td>
<td>Shir-jing Ho</td>
<td>Phase I/II</td>
<td>10-Aug-2008</td>
</tr>
<tr>
<td>SAVE ABDOS</td>
<td>A multinational, Multicenter, randomized, Double Blind Study comparing the Efficacy and Safety of AVE5026 with enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery.</td>
<td>EFC 5026</td>
<td>Sanofi-Aventis</td>
<td>Beng Hock Chong</td>
<td>13-Aug-2008</td>
<td>Closed-No Participants</td>
</tr>
<tr>
<td>AMPLIFY EXTENSION</td>
<td>A SAFETY AND EFFICACY TRIAL EVALUATING THE USE OF APIXABAN FOR THE EXTENDED TREATMENT OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM</td>
<td>185-057</td>
<td>Bristol-Myers Squibb</td>
<td>Beng Hock Chong</td>
<td>Phase III</td>
<td>24-Sep-2008</td>
</tr>
<tr>
<td>Study</td>
<td>Description</td>
<td>Code</td>
<td>sponsor</td>
<td>Principal Investigator</td>
<td>Phase</td>
<td>Start Date</td>
</tr>
<tr>
<td>-------------------------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>------</td>
<td>--------------------</td>
<td>------------------------</td>
<td>---------</td>
<td>------------</td>
</tr>
<tr>
<td>R-IE</td>
<td>A phase IV study to evaluate the treatment response</td>
<td>185-056</td>
<td>R-IE Westmead</td>
<td>Sundra Ramanathan</td>
<td>Phase II</td>
<td>28-Oct-2008</td>
</tr>
<tr>
<td>AMPLIFY TREATMENT</td>
<td>A Safety and Efficacy Trial Evaluating the Use of Apixaban in the Treatment of Symptomatic Deep Vein Thrombosis and Pulmonary Embolism</td>
<td>185-056</td>
<td>Bristol-Myers Squibb</td>
<td>Beng Hock Chong</td>
<td>Phase III</td>
<td>01-Jan-2009</td>
</tr>
<tr>
<td>Thromboprophylaxis in Haematology</td>
<td>Pilot Study into the safety and efficacy of thromboprophylaxis and treatment of thromboembolism in patients with haematological malignancies</td>
<td>NA</td>
<td>SESLHD Central Network Cancer Services</td>
<td>Shir-jing Ho</td>
<td>N/A</td>
<td>01-Jan-2009</td>
</tr>
<tr>
<td>ALLG Tissue Bank</td>
<td>AMP Leukaemia and Lymphoma Tissue Bank A joint research initiative of ALLG and the Leukaemia Foundation</td>
<td>ALLG Tissue Bank</td>
<td>ALLG</td>
<td>Shir-jing Ho</td>
<td>N/A</td>
<td>27-Jan-2009</td>
</tr>
<tr>
<td>SAVE-KNEE TSH</td>
<td>A Multinational, Multicentre, Randomised, Double-blind Study Comparing the Efficacy and Safety of AVE5026 with enoxaparin for the prevention of Venous Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery</td>
<td>EFC10571</td>
<td>Sanofi-Aventis</td>
<td>Beng Hock Chong</td>
<td>Phase III</td>
<td>18-Feb-2009</td>
</tr>
<tr>
<td>SAVE-ABDO TSH</td>
<td>A Multinational, Multicentre, Randomised, Double Blind Study comparing the Efficacy and Safety of AVE5026 with enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery</td>
<td>EFC8520</td>
<td>Sanofi-Aventis</td>
<td>Beng Hock Chong</td>
<td>Phase III</td>
<td>03-Mar-2009</td>
</tr>
<tr>
<td>RAPIMED</td>
<td>AMG/MDS 2000601</td>
<td>SAVE-ONC</td>
<td>BP2333 Stage 1</td>
<td>ALLG NHL21</td>
<td>COMFORT 1</td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>----------------</td>
<td>----------</td>
<td>---------------</td>
<td>------------</td>
<td>-----------</td>
<td></td>
</tr>
<tr>
<td>Chong, Beng</td>
<td>Randomised, Double-blind, Placebo-controlled Study</td>
<td>A Multi-national, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AVE8026 in the Prevention of Venous Thromboembolism (VTE) in Cancer Patients at High Risk for VTE and who are Undergoing Chemotherapy.</td>
<td>A Two-stage phase 1b study to Investigate the Pharmacokinetics in Patients with Follicular Lymphoma 3</td>
<td>Early Treatment Intenification with R-ICE</td>
<td>A Randomised, Double-blind, Placebo-controlled Study of the JAK Inhibitor INC008424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis</td>
<td></td>
</tr>
<tr>
<td>SLSHD Cancer Services</td>
<td>AMG, MDS</td>
<td>Sanofi-Aventis, AstraZeneca</td>
<td>Sunovia, Rarana than Jho</td>
<td>ALUG</td>
<td>Incyte Corporation</td>
<td></td>
</tr>
<tr>
<td>David</td>
<td>NIA</td>
<td>Beng-Hock Chong</td>
<td>Beng-Hock Chong</td>
<td>Beng-Hock Chong</td>
<td>Beng-Hock Chong</td>
<td></td>
</tr>
<tr>
<td>Central Network Services</td>
<td>N/A</td>
<td>Phase</td>
<td>Closed-No</td>
<td>Closed-No</td>
<td>Closed-No</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CTBP-C</td>
<td></td>
<td>Participants</td>
<td>Participants</td>
<td>Participants</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Closed-No</td>
<td></td>
<td>1b</td>
<td>1b</td>
<td>1b</td>
<td></td>
</tr>
<tr>
<td></td>
<td>N/A</td>
<td></td>
<td>01-Jul-2009</td>
<td>01-Jul-2009</td>
<td>01-Jul-2009</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Archived</td>
<td></td>
<td>Archived</td>
<td>Archived</td>
<td>Archived</td>
<td></td>
</tr>
<tr>
<td></td>
<td>98</td>
<td></td>
<td>01-Aug-2009</td>
<td>01-Aug-2009</td>
<td>01-Aug-2009</td>
<td></td>
</tr>
<tr>
<td></td>
<td>N/A</td>
<td></td>
<td>01-Aug-2009</td>
<td>01-Aug-2009</td>
<td>01-Aug-2009</td>
<td></td>
</tr>
<tr>
<td>Study Code</td>
<td>Study Title</td>
<td>Study Design</td>
<td>Participants</td>
<td>Study Phase</td>
<td>Enrollment Dates</td>
<td>Follow-up Dates</td>
</tr>
<tr>
<td>------------</td>
<td>-------------</td>
<td>--------------</td>
<td>--------------</td>
<td>-------------</td>
<td>-----------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>ONTX-3</td>
<td>A Randomised, Double-Blind, Double-Dummy, Parallel Group Study to Compare LMWH and subcutaneous injections of fondaparinux in the Treatment of Venous Thromboembolic Disease in the Medical Setting</td>
<td>Open-label, multicentre, randomised, double-blind, controlled trial</td>
<td>&gt;1000 patients</td>
<td>Phase III</td>
<td>01-Jan-2010</td>
<td>01-Feb-2010</td>
</tr>
<tr>
<td>STG-Private</td>
<td>SAVE ADDO</td>
<td>Study comparing the efficacy and safety of LMWH and fondaparinux in the prevention of VTE in patients undergoing major Abdominal surgery</td>
<td>&gt;1000 patients</td>
<td>Phase III</td>
<td>01-Mar-2010</td>
<td>01-Apr-2010</td>
</tr>
<tr>
<td>AMG20800009</td>
<td>A Prospective, Open-label, Multicentre Study to Evaluate the Safety and Efficacy of AMG-208 in Subjects With Myelodysplastic Syndrome or Acute Myeloid Leukaemia Who Are Undergoing Induction Therapy</td>
<td>Open-label, multicentre, randomised, double-blind, controlled trial</td>
<td>&gt;1000 patients</td>
<td>Phase IV</td>
<td>01-May-2010</td>
<td>01-Jun-2010</td>
</tr>
<tr>
<td>ALLG CL5</td>
<td>An Australasian, Phase II/III Randomised, Open-label, Multicentre, Controlled, Randomized Parallel-arm Study Investigating the Efficacy and Safety of Romosozumab (Histrelin) in Postmenopausal Women With Osteoporosis</td>
<td>Open-label, multicentre, randomised, double-blind, controlled trial</td>
<td>&gt;1000 patients</td>
<td>Phase III</td>
<td>01-Jul-2010</td>
<td>01-Aug-2010</td>
</tr>
<tr>
<td>BR2233 Stage 3</td>
<td>A two-stage, phase 1b study to investigate the pharmacokinetics of patients with follicular lymphoma (FL) as part of maintenance treatment</td>
<td>Open-label, multicentre, randomised, double-blind, controlled trial</td>
<td>&gt;1000 patients</td>
<td>Phase III</td>
<td>01-Sep-2010</td>
<td>01-Oct-2010</td>
</tr>
<tr>
<td>HX015ALVTE Study</td>
<td>The vedolizumab HX015ALVTE Study</td>
<td>Open-label, multicentre, randomised, double-blind, controlled trial</td>
<td>&gt;1000 patients</td>
<td>Phase III</td>
<td>01-Nov-2010</td>
<td>01-Dec-2010</td>
</tr>
<tr>
<td>Project Code</td>
<td>Description</td>
<td>Sponsor</td>
<td>Investigator</td>
<td>Phase</td>
<td>Start Date</td>
<td>Status</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>---------</td>
<td>--------------</td>
<td>-------</td>
<td>------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>PATH CLBH589E2301</td>
<td>A Phase III randomized, double blind, placebo controlled multi-centre study of panobinostat for maintenance of response in patients with Hodgkin's Lymphoma who are at risk for relapse after high dose chemotherapy and autologous stem cell transplant</td>
<td>Novartis</td>
<td>Shir-jing Ho</td>
<td>III</td>
<td>01-Jul-2010</td>
<td>Closed-No Participants</td>
</tr>
<tr>
<td>CLL 11 BO21004</td>
<td>An open-label, multi-centre, three arm randomized, phase III study to compare the efficacy and safety of RO5072759+chlorambucil (GCb), rituximab + Chlorambucil (RClb) or chlorambucil (Clb) alone in previously untreated CLL patients with comorbidities.</td>
<td>Roche</td>
<td>Ramanathan</td>
<td>III</td>
<td>01-Sep-2010</td>
<td>Active-In Follow-up</td>
</tr>
<tr>
<td>The EINSTEIN VTE treatment study (St George Private Hospital)</td>
<td>Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism. The Einstein VTE study</td>
<td>Bayer</td>
<td>Beng Hock Chong</td>
<td>III</td>
<td>01-Sep-2010</td>
<td>Closed-No Participants</td>
</tr>
<tr>
<td>M07-001 PNH Registry</td>
<td>A global, observational, non-interventional study collecting effectiveness, safety and quality of life data on patients with Paroxysmal Nocturnal Haemoglobinuria (PNH) Disease.</td>
<td>ALEXION</td>
<td>Beng Hock Chong</td>
<td>N/A</td>
<td>14-Feb-2011</td>
<td>Active-Recruiting</td>
</tr>
<tr>
<td>MDS4</td>
<td>A randomised Phase II study comparing the efficacy of Sazacitidine alone versus combination therapy with lenalidomide and Sazacitidine in patients with higher risk myelodysplastic syndromes (MDS) and low marrow blast count acute myeloid leukaemia (AML)</td>
<td>ALLG MD5</td>
<td>Shir-jing Ho</td>
<td>II</td>
<td>15-Feb-2011</td>
<td>Active-Recruiting</td>
</tr>
<tr>
<td>ALLG MM11</td>
<td>A phase 3, Multicentre, Randomized, Controlled study to determine the efficacy and safety of Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) versus Melphalan (200mg/m2) followed by stem cell transplant in newly diagnosed multiple Myeloma subjects.</td>
<td>ALLG</td>
<td>Ramanathan</td>
<td>III</td>
<td>17-Feb-2011</td>
<td>Active-In Follow-up</td>
</tr>
<tr>
<td>Study ID</td>
<td>Title</td>
<td>Sponsor</td>
<td>Principal Investigator</td>
<td>Phase/Clinical Group</td>
<td>Status</td>
<td>Start Date</td>
</tr>
<tr>
<td>---------</td>
<td>-----------------------------------------------------------------------</td>
<td>---------</td>
<td>------------------------</td>
<td>----------------------</td>
<td>--------</td>
<td>------------</td>
</tr>
<tr>
<td>GAUDI BO21000</td>
<td>An open-label, multi-centre, randomised, phase Ib study to investigate the safety and efficacy of RO5072759 given in combination with CHOP, FC or Bendamustine chemotherapy in patients with CD20+ B-cell follicular non-Hodgkin's lymphoma.</td>
<td>Roche</td>
<td>Sundra Ramanathan</td>
<td>Phase Ib</td>
<td>17-Mar-2011</td>
<td>Active-in Follow-up</td>
</tr>
<tr>
<td>Amgen MM Observational Study</td>
<td>An Observational Study of Neutropenia in Subjects Being Treated for Relapsed or Relapsed/Refractory Multiple Myeloma</td>
<td>Amgen</td>
<td>Beng Hock Chong</td>
<td>N/A</td>
<td>11-May-2011</td>
<td>Active-Recruiting</td>
</tr>
<tr>
<td>ITP Registry</td>
<td>A Multi-centre, prospective disease registry for adults diagnosed with primary immune thrombocytopenia purpura (ITP) in international countries.</td>
<td>CTBR01.7</td>
<td>Chong, Beng Hock - SESLHD Central Network Cancer Services</td>
<td>Phase III</td>
<td>13-May-2011</td>
<td>Active-Recruiting</td>
</tr>
<tr>
<td>REMARC NHL25</td>
<td>DOUBLE BLIND RANDOMIZED PHASE III STUDY OF LENALIDOMIDE (REVUMID®) MAINTENANCE VS. PLACEBO IN RESPONDING ELDERLY PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA AND TREATED WITH R-CHOP IN FIRST LINE</td>
<td>ALLG</td>
<td>Sundra Ramanathan</td>
<td>Phase III</td>
<td>16-May-2011</td>
<td>Active-Recruiting</td>
</tr>
<tr>
<td>Red Cross Sickle Cell Audit</td>
<td>Audit of sickle cell disease patients in Sydney (A transfusion Laboratory Based Perspective)</td>
<td>St George Hospital - Haematology</td>
<td>Shir-Jing Ho</td>
<td>N/A</td>
<td>28-Jun-2011</td>
<td>Closed-No Participants</td>
</tr>
<tr>
<td>SAWYER BO25341</td>
<td>An Adaptive, comparative, randomised, parallel-group, multi-centre, Phase 1b study of subcutaneous (SC) rituximab versus intravenous (IV) rituximab both in combination with chemotherapy (flurarabine and cyclophosphamide), in patients with previously untreated CLL</td>
<td>Roche</td>
<td>Xavier Badoux</td>
<td>Phase Ib</td>
<td>04-Jul-2011</td>
<td>Active-in Follow-up</td>
</tr>
<tr>
<td>Study Reference</td>
<td>Study Title</td>
<td>PI(s)</td>
<td>Sponsor(s)</td>
<td>Start Date</td>
<td>Condition Status</td>
<td></td>
</tr>
<tr>
<td>-----------------</td>
<td>----------------------------------------------------------------------------</td>
<td>-------------------------------</td>
<td>------------------</td>
<td>------------</td>
<td>-----------------</td>
<td></td>
</tr>
<tr>
<td>ALLG CML10 RESIST</td>
<td>Response Post Tyrosine Kinase Inhibitor: Assessment of Sensitivity and Therapeutic Response to Next-Line Therapy in CML: The Australasian RESIST study</td>
<td>ALLG Shih-ting Ho N/A 13-Jul-2011</td>
<td>Active-Recruiting</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENESTxtd: CAMN107E2401</td>
<td>Extending molecular responses with Nilotinib in newly diagnosed chronic myeloid leukaemia (CML) patients in chronic phase (ENESTxtd)</td>
<td>CAMN107E2401 Novartis Sundra Ramanathan Phase IIIb 01-Dec-2011</td>
<td>Active-Recruiting</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SEALS LABORATORY ACTIVITIES

The laboratory is NATA AS4633 (ISO 15189) and AS/NZS ISO 9001:2000 accredited and provides a range of laboratory services in haematology including automated blood cell analysis and morphology, bone marrow examination, flow cytometry, routine and special coagulation assays, transfusion medicine and haemopoietic stem cell transplantation.

An area reference services is provided for intrinsic factor antibodies, whole blood aggregation and heparin induced anti-platelet antibodies.

A state wide reference service is provided for drug-dependent and autoimmune anti-platelet antibodies.

The Department of Haematology is accredited by the Royal College of Pathologists of Australasia for supervised registrar training in Haematology, and actively participates in training junior laboratory staff.

The Department is a centre of excellence catering for the diagnostic, clinical, research and teaching activities of the SESLHD.
BASIC AND TRANSLATIONAL RESEARCH LABORATORY (St George Clinical School)

The Haematology Department of Medicine Research Laboratory conducts original research into key aspects of haematopoiesis and blood diseases. As such, the laboratory works on two related areas:

a) Basic research into gene and transcriptional regulation in haematopoiesis (especially megakaryocyte development and platelet production). This includes work on the molecular and cellular mechanisms of cytopenic and other haematological disease.

b) Translation Research into potential therapeutic strategies to treat conditions such as heparin-induced thrombocytopenia, thrombosis and immune thrombocytopenia.

Over the past 10 year this laboratory has made great progress in the understanding of the genetic control of platelet production and cardiac cell development, particularly transcription factor functions in regulation of these processes. For example we were the first to clone human FOG2, a key cardiac transcript factor. In addition, significant progress has been made in the understanding of the mechanisms of drug-induced thrombocytopenia and in the design of potential therapies for heparin-induced thrombocytopenia and thrombosis.

Research Projects:
1. Transcriptional regulation in haematopoietic cells: understanding the basic genetic programs that determine cell fate is essential for the design of novel therapeutic strategies. The principal findings of this project are:
   - ETS transcription factors in conjunction with kinase-mediated extracellular signalling control the expression of GPIIb, an essential platelet-specific receptor protein (1).
   - Expression of the megakaryocyte/platelet-specific receptor GPVI is controlled by the transcription factors GATA-1, Fli-1 and Sp1 (2)
- Activation of megakaryocyte-specific promoters depends on the nuclear import of the transcription factor FlI-1 (3)
- A nuclear targeting sequence in the transcription factor PU.1 is required for the control of myeloid genes (4)
- P45-NF-E2 mediates the enhancement of megakaryocyte differentiation and platelet production in vivo (5)
- A nuclear localization signal in the transcription factor p45-NF-E2 is essential for platelet production (6)

2. Drug-induced thrombocytopenia: A variety of drugs commonly used in the clinic can result in the production of drug-dependent antibodies that cause a marked drop in platelet numbers, hence leading to bleeding and potentially serious internal haemorrhage. It’s important to elucidate the mechanisms of this disease in order to improve patient care. The main findings of the Medicine Lab in this respect include:
- Fine mapping of the binding sites of quinine-dependent antibodies on the platelet receptor complex GPIb/IX (7)
- Development of a novel mouse model to evaluate drug-induced antibody platelet destruction in vivo and to test the efficacy of treatments (8)
- Finding that drug-induced antibodies also cause a drop in platelet production by damaging platelet-producing cells (megakaryocytes) (9)

3. Heparin-induced thrombocytopenia/thrombosis: Heparin is widely used as an anticoagulant in clinical settings. One of the serious side effects of heparin use is the occurrence of an immune reaction in some patients. This gives rise to a heparin-dependent antibody that attacks platelets causing platelet destruction and thrombus formation. The following findings have emerged from this research area:
- Identification of mutations that enhance the binding of pathogenic antibodies to platelet factor. This is important as a diagnostic tool, since there is a pressing need to differentiate between harmless heparin-dependent antibodies (non-pathogenic) and those that cause platelet damage. Development of a mini-antibody that prevents platelet destruction by protecting the platelets from the antibody-mediated attack.

4. Cardiac transcription factors and cardiac stem cells. Some key transcription factors involved in blood development have counterpart in the cardiac system, these include FOG-2 and GATA-4. Some time ago our laboratory cloned one of these factors, FOG-2 (Holmes et al, hFOG-2, a Novel Zinc Finger Protein, Binds the Co-repressor mCtBP2 and Modulates GATA-mediated Activation, JBC, 1999). Some of the key findings from this project include:
- Identification of the mechanisms mediating nuclear trafficking of GATA-4 (10)
- Establishment of a murine myocardial ischemic model to analyse the migration of cardiac stem cells to sites of injury (11, 12)
- Finding that FOG-2 is modulated by a post-translational modification (SUMOylation). This modification controls the magnitude on FOG-2 activity on its target genes.
Collaborations
The Haematology Department of Medicine Research Laboratory collaborates with a number of researchers. Some of these projects include:
- Collaboration in nuclear localization studies with the laboratory of Prof. David Jans at Monash University (6)
- With Prof. Merlin Crossley’s lab at Sydney University on transcriptional regulation in blood cells (13, 14)
- With Prof. Miles Davenport at the Centre for Vascular Research, UNSW regarding mathematical models of platelet destruction (8)

Current Projects:
1. **Platelet production from haematopoietic stem cells: How to enhance platelet numbers.** There is increased demand for platelet transfusions in several patient groups such as AML patients, stem cell transplant recipients and those undergoing chemotherapy. In addition, many patients refractory to heterologous platelet transfusions would greatly benefit from a supply of autologous platelets produced in vitro. We have demonstrated that we can produce platelets in vitro and that the production can be augmented by forced expression of transcription factors (5, 6). The current project aims to increase platelet production but over expression of the master regulator GATA-1.

2. **Drug-induced immune thrombocytopenia and immune thrombocytopenia: the current research topics in this area include:**
   - Elucidation of the mechanisms of drug-dependent antibody cellular damage
   - Investigations of the effects of immune thrombocytopenia antibodies on megakaryocyte differentiation and platelet biology
   - Effects of antibodies on platelet apoptosis
   - Mapping of the binding sites of immune thrombocytopenia antibodies on platelet receptors

3. **Heparin-induced thrombocytopenia.** We have developed a small antibody that prevents platelet destruction mediated by heparin-dependent antibodies. This project currently continues with an animal model to test the effectiveness of this molecule. In addition we are testing a number of peptides that may inhibit the heparin-induced antibodies binding to platelets.

4. **Transcriptional regulation: this project aims to expand our understanding of transcription factor regulation.** In particular, how SUMO modification modulates the transcriptional activity of GATA-1, FOG-1 and FOG-2 will be studied in detail.

5. **Platelet aggregation and ADP signalling.** We have identified molecular targets that may prevent platelet aggregation after ADP stimulation. We aim to map these molecules and determine the signalling pathways that give rise to this observation. This research may prove valuable to understand platelet aggregation and also potential inhibitors of unwanted clotting.
Supervision

The following students have completed their PhD Thesis work in the Medicine Lab:
- Buckle, Andrew. Physical interactions of the heart : FHL2, FOG-2 and GATA-4 (2005)
- Philips, Alana. Molecular insights into the biological role / mechanisms of GATA-4 and FOG-2 in normal cardiac function and in cardiac hypertrophy (2007)
- Pan, Shu. Functional studies of transcription factors GATA-1, Fli-1 and FOG-1 in Megakaryocyte development. (2007)
- Fock, Eeling. Molecular regulation and enhancement of megakaryopoiesis and thrombopoiesis by the p45 subunit of NF-E2. (2008)
- Carter, Daniel. Transcriptional regulation of cardiac development and cardiac hypertrophy (2012)

Selected Publications


For more information see PUBLICATIONS: B H Chong.
RESEARCH GRANTS

Category I - Nationally Competitive Grants:

NHMRC Program Grants:

Program Grant NHMRC 455395.
Vascular Biology: 2007-2011
$14,516,629

CN Chesterman, RK Andrews, MC Berndt, **BH Chong**, et al.
Vascular Biology 209618: 2001-2006
$10,000,000

CN Chesterman, **BH Chong**, PJ Hogg, DA Owensby, LM Khachigian
$3,066,000

NHMRC Project Grants:

Project Grant NHMRC APP1012409, RM 08796, InfoEd Ref: RG102962
**BH Chong**, M Davenport
Drug-induced immune thrombocytopenia Jan 2011-Dec 2013
$491,706

Project Grant NHMRC RM09942 APP1028803BH
**BH Chong**, C Parish
$631,010

Australian Research Grant

**BH Chong**
Role of GATA-4, FOG-2 and FHL2 in transcriptional regulation of cardiac myocyte development.
2005-2007
$240,000
Category II - Other competitive grants:
ANZSBT Research Grant  

*S J Ho*  
People involved in research in transfusion medicine and science undertaken in Australia and New Zealand. 2011  

$33,000

NSW Cancer Institute  

*S Ramanathan*  
Cancer Trials Nurses and Data Manager’s Grant 2010/11  

$165,360

NSW Cancer Institute  

*S J Ho*  
Cancer Trials Nurses and Data Manager’s Grant 2010/11  

$82,680

The Department of Health and Aging, Australian Government, via the Specialist Training Program, Royal College of Pathologists of Australasia  

*S-H Lee*  
2010-2011  

$46,000

NSW / ACT Morphology Training Network, Royal College of Pathologists of Australasia  

P Kumar, *S-H Lee, D Talaulikar*  
Specialist Training Program Rural Project # 325 2011-2013  

$40,000

St George Medical Research Foundation Post-Graduate Scholarship  

*P Choi*  
2010  

$30,000 per year
UNSW Gold Star Award

BH Chong
2010
$40,000

National Heart Foundation grant

BH Chong, RL Ward, OT Chisholm
$139,458

UNSW Medical Facility Dean’s Initiative award

BH Chong, T Brighton, J Myburg et al
2006 - 2007
$250,000

Category III – Industry and other research funding:

Industry Funded Clinical Research Projects:

– BH Chong, S Ramanathan, F Roncolato, X Badoux, S-J Ho, A Hugman, M Harvey, Principal Investigators.
– 2010 Grant Funds: $894,700
– 2011 Grant Funds: $387,900

International Research Grants:

Singapore National Medical Research Council Grant

BH Chong
Development of platelet inhibitors for treatment of coronary heart disease 2001 – 2005
$2,264,000
**Equipment Research Grants:**

UNSW Major Research Equipment and Infrastructure Initiative
L Khaohugian, CN Chesterman, P Hogg, W Jessup, **BH Chong**, et al
$1,100,000

NHMRC Equipment Grant
**BH Chong**, S Krulas, B Allen, et al
AKTA Explorer System 2004
$65,000

NHMRC Equipment Grant
B Allen, **BH Chong**, P Cistulli, et al
Bio-Rad Cell Map Confocal Imaging System 2003
$151,000
### COMMERCIAL FUNDING – CURRENTLY HELD BH CHONG:

<table>
<thead>
<tr>
<th>TITLE / INVESTIGATORS</th>
<th>SOURCE</th>
<th>PERIOD</th>
<th>FUNDS (total)</th>
</tr>
</thead>
<tbody>
<tr>
<td>EINSTEIN VTE treatment study: Oral direct oral factor Xa inhibitor Rivaroxaban in patients with acute symptomatic deep vein thrombosis and pulmonary embolism (St. George Hospital) BH Chong</td>
<td>Bayer / Covance</td>
<td>2007-2012</td>
<td>$440,000.00</td>
</tr>
<tr>
<td>EINSTEIN VTE treatment study: Oral direct oral factor Xa inhibitor Rivaroxaban in patients with acute symptomatic deep vein thrombosis and pulmonary embolism. (Sutherland Hospital) BH Chong</td>
<td>Bayer / Covance</td>
<td>2007-2012</td>
<td>$150,000.00</td>
</tr>
<tr>
<td>AMPLIFY TREATMENT: A Safety and Efficacy Trial Evaluating the Use of Apixaban in the Treatment of Symptomatic Deep Vein Thrombosis and Pulmonary Embolism BH Chong</td>
<td>MS/Pfizer/PPD (Amplify Treatment)</td>
<td>2009-12</td>
<td>$125,000.00</td>
</tr>
<tr>
<td>AMPLIFY EXTENSION:: A safety and efficacy trial evaluating the use of Apixaban for the extended treatment of deep vein thrombosis and pulmonary embolism BH Chong</td>
<td>MS/Pfizer/PPD (Amplify Extension)</td>
<td>2008–12</td>
<td>$180,000.00</td>
</tr>
<tr>
<td>The Edoxaban HOKUSAI VTE Study: A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/ Edoxaban Versus (LMW) Heparin/Warfarin In Subjects with Symptomatic Deep-Vein Thrombosis and/or Pulmonary Embolism. BH Chong</td>
<td>Daiichi-Sankyo</td>
<td>2010-2012</td>
<td>$60,000.00</td>
</tr>
<tr>
<td>ASPIRE: Aspirin to prevent recurrent venous thromboembolism. A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial oral anticoagulation to prevent recurrent venous thromboembolism. BH Chong</td>
<td>NHMRC-CTC</td>
<td>2003-2012</td>
<td>$5,000</td>
</tr>
<tr>
<td>(Eltrombopag Extended Dosing Study): An extension study of eltrombopag olamine (SB-497115-GR) in adults, with idiopathic thrombocytopenic purpura (ITP), previously enrolled in an eltrombopag study. BH Chong</td>
<td>GSK</td>
<td>2007-2013</td>
<td>$85,000 for 2007-2012</td>
</tr>
<tr>
<td>Study Title</td>
<td>Company</td>
<td>Duration</td>
<td>Funding Details</td>
</tr>
<tr>
<td>---------------------------------------------------------------------------</td>
<td>---------------</td>
<td>----------------</td>
<td>----------------------------------</td>
</tr>
<tr>
<td>A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis. BH Chong</td>
<td>Incyte Corporation</td>
<td>2010-2014</td>
<td>$48,000 for 2010-2012</td>
</tr>
<tr>
<td>A Prospective, Phase IV, Open-Label, Multi-Center Study Evaluating Changes in Bone Marrow Morphology in Adult Subjects Receiving Romiplostim for the Treatment of Thrombocytopenia Associated with Immune (Idiopathic) Thrombocytopenia Purpura (ITP). BH Chong</td>
<td>Amgen</td>
<td>2010-2015</td>
<td>$42,000 for 2010-2012</td>
</tr>
<tr>
<td>A global, observational, non-interventional study collecting effectiveness, safety and quality of life data on patients with Paroxysmal Nocturnal Haemoglobinuria (PNH) Disease. BH Chong</td>
<td>Alexion</td>
<td>2010-2015</td>
<td>$35,000 for 2010-2012</td>
</tr>
<tr>
<td>International ITP Registry: A Multi-centre, prospective disease registry for adults diagnosed with primary immune thrombocytopenia purpura (ITP) Asia-Pacific, Middle Eastern and S American countries. BH Chong</td>
<td>Chong BH: Chair, Steering Committee. Unrestricted grant from GSK</td>
<td>2011-2021</td>
<td>~$180,000 for 2011-12</td>
</tr>
<tr>
<td>An Observational Study of Neutropenia in Subjects Being Treated for Relapsed or Relapsed/Refractory Multiple Myeloma. BH Chong</td>
<td>Amgen</td>
<td>2011-2015</td>
<td>$7,000 for 2011:</td>
</tr>
</tbody>
</table>
PUBLICATIONS

BH CHONG


46. Fock E, Yan F, **Chong BH**., ‘Proplatelet production from haematopoietic stem cells enhanced by NF-E2 overexpression.’ *Cytotherapy* 2006; 8: Suppl. 1.


64. Tait AS, Cranmer SL, Jackson SP, Dawes IW, Chong BH. ‘Phenotype changes resulting in high-affinity binding of von Willebrand factor to recombinant glycoprotein Ib-IX: analysis of the platelet-type von Willebrand disease mutations’, Blood, 98, 2001; No.6, 1812-1818.


Other published materials (books, book chapters)


Selected Peer-Reviewed Publications


Other published material (book chapters)


S Ramanathan

Original Peer-Reviewed Journal Publications


SJ HO

Original Peer-Reviewed Journal Publications


---

**RONCOLATO**

Original Peer-Reviewed Journal Publications


X BADOUX

Original Peer-Reviewed Journal Publications


P CHOI

Original Peer-Reviewed Journal Publications


N CHAPMAN

Original Peer-Reviewed Journal Publications


C HICKS

Original Peer-Reviewed Journal Publications

2. J. Case, C. Hicks, A. Trickett, YL. Kwan, A. Manoharan. ‘The Expansion of Megakaryocytes Progenitors From CD34+ Enriched Mobilised Peripheral Blood Stem Cells is Inhibited by Flt3-L.’ *Journal of Cytokine and Interferon Research.* 2006; 26;76-82.
3. C Hicks, R. Wong, A. Manoharan, YL Kwan. ‘Analysis of viable CD133+/CD34+ and CD34+ stem cell subsets in prediction of hematopoietic engraftment in multiple patients undergoing peripheral blood stem cell transplantation.’ May 2006; *International Society of Cellular Therapy (ISCT).* Berlin.
4. C. Hicks, R. Wong, A. Manoharan, Y.L. Kwan. ‘Viable CD34+/CD133+ Blood Progenitor Cell Dose as a Predictor of Haematopoietic Engraftment in Multiple Myeloma Patients undergoing Autologous Peripheral Blood Stem Cell Transplantation.’ *Annals of Hematology.* 2007; 86(8); 591-598.
5. **Christine Hicks**, Arend Isaacs, Rose Wong, **Beng H Chong**. ‘CXCR4 expression on transplanted peripheral blood CD34⁺ cells: Relationship to engraftment after autologous transplantation in a cohort of Multiple Myeloma patients.’ *Annals of Hematology*. 2011; 90; 547-555.


---

**R Wong**

*Original Peer-Reviewed Journal Publications*


---

**S Smith**

*Original Peer-Reviewed Journal Publications*

1. Trickett AE, **Smith S**, Kwan YL. ‘Accurate calculation of blood volume to be processed by apheresis to achieve target CD34⁺ cell numbers for PBPC transplantation.’ *Cytotherapy*, 2001;3(1):5-10.


---

**R Gemmell**

*Original Peer-Reviewed Journal Publications*


**J PERDOMO**

Original Peer-Reviewed Journal Publications


Other published material (books, book chapters, reviews...)

PRESENTATIONS: SCIENTIFIC MEETINGS AND CONFERENCES


BH CHONG


2. Chong BH. ‘Future perspectives in ITP Management’ Corporate ITP Symposium, held in conjunction with Taiwan Society of Haematology meeting; Taipei, Taiwan April, 2011.


6. Chong BH. ‘Understanding Disease Mechanisms is the key to better treatment of immune Thrombocytopenia.’ Australian Vascular Biology Society Annual Scientific Meeting, September 15-18, 2011, Bowral, NSW.


26. Jose Perdomo and Beng H. Chong (invited lecture). ‘SUMOylation and Transcriptional Regulation’, 2010, School of Biomedical Sciences, University of Newcastle, Australia.


44. Chong BH. ‘Autoimmune thrombocytopenia.’ The proceedings of the International Haematology Society 2004 Nagoya.


**SI HO**


P CHOI


N CHAPMAN


R RISTUCCIA


C HICKS

1. Christine Hicks, Jamie Case, Annette Trickett, YL Kwan, A. Manoharan. ‘Optimising the ex vivo expansion of megakaryocyte precursors with CFG-Mk potential from CD34+ enriched PBSC.’ Abstract. HSANZ 2003. NZ.


5. R. Wong, A. Abdullah, C. Hicks, A. Manoharan, YL Kwan. ‘Correlation between CD34+ stem cells and colony-forming units (CFU-GM) at time of harvest and their viability at transplantation, and haematopoietic engraftment kinetics after peripheral blood stem cell transplantation.’ Abstract. HSANZ, Sydney 2005.

6. C. Hicks, A. Abdullah, R. Wong, A. Manoharan, YL Kwan. ‘Viable CD133/CD34+ and CD34+ stem cell subsets in prediction of haematopoietic engraftment in multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation.’ Abstract HSANZ. Sydney 2005.

7. C. Hicks, M. Johnstone, P. Butler, YL Kwan, A. Manoharan. ‘Comparison of Tc-99m MIBI (sestaMIBI) uptake by transformed and multiple myeloma (MM) plasma cells.’ Abstract. HSANZ. Sydney, 2005.


S SMITH


R WONG


2. Rose Wong, Sundra Ramanthan, Beng H Chong. ‘The expression levels of transcription factors in different subsets of human peripheral blood stem cells may contribute to haematopoietic engraftment.’ Annual Meeting, International Society for Stem Cell Research, Cairns, June 2007.


4. Rose Wong, Alhossain Abdallah, Christine Hicks, Arumugam Manoharan and Yiu Lam Kwan. ‘Correlation between CD34 (+) stem cells and colony-forming units -GM (CFU-GM) at time of harvest and their viability at transplantation, and haemopoietic engraftment kinetics after peripheral blood stem cell transplantation.’ Haematology Society of Australia & New Zealand Conference, Sydney; October 2005.


R GEMMELL


2. Lisa Parry, R. Gemmell, Prof BH Chong, Dr SJ Ho. ‘Assessment of quick spin centrifugation and the impact on routine coagulation results.’ HAA 2008.


9. Jose Perdomo and Beng H. Chong (invited lecture). ‘SUMOylation and Transcriptional Regulation’, 2010, School of Biomedical Sciences, University of Newcastle, Australia.


COMMUNITY ENGAGEMENT

BH Chong:

NHMRC Project Grant assessment panel member 2008 and 2010
Member of the Board of St George Medical research Foundation and Deputy Chair, Scientific Advisory Committee, St George Medical Research Foundation.
Member, Medical and Dental Appointments Committee, St George Hospital.
Member of Clinical Council, St George Hospital, Sydney
Chair (2005) and Member (2003-2009), Scientific and Standardisation Committee of International Society of Thrombosis and Haemostasis (ISTH)
Co-chair, Platelet Immunology Subcommittee, International Society of Thrombosis and Haemostasis; Council member, Asia-Pacific Society of Thrombosis and Haemostasis;
Vice-President, Australian Bid Committee and 2019 congress, International Society of Thrombosis and Haemostasis
Member of Editorial Boards of International Journals: (1) Thrombosis Journal, (2) Asia-Pacific Journal of Hematology and Oncology.

SH Lee:

Member, Editorial Board, Pathology, 2000 - present
Chair, Organising Committee, 3rd Asian Colloquium on Standardisation and Harmonization in Laboratory Medicine, Singapore, 2001
Chair, Organising Committee, 1st Asia-Pacific Medical Education Conference, Singapore 2003
Counsellor (Australia), International Society for Laboratory Hematology, 2004-2009
Program Co-Chair, ISLH 2006, Amsterdam, Netherlands, 2006
Co-Executive Director and Member, Program Committee, ISLH 2007, Miami, USA, 2007
Member, Editorial Board, International Journal of Laboratory Hematology (IJLH), 2007 – 2010
Program Co-Chair, ISLH 2008, Sydney, Australia, 2008
Member. International Editorial Advisory Board, Malaysian Journal of Pathology, 2008 - present
Member Board of Directors, International Society of Laboratory Hematology, 2009 - present
Vice-President, International Council for Standardization in Hematology, 2009 - present
Co-Chief Editor, International Journal of Laboratory Hematology, 2010 - present
BH Chong - Awards and Honours- 2010-2011

2. Chong, BH. Research Award from Peoples’ Republic of China to BH Chong for his contributions to development of research and technology in Zhejiang Province, PR of China.
3. Chong, BH. Royal College of Pathologists of Australasia South-East Asia Visiting Lecturer/Professor Award.

X Badoux – Awards -2011

1. Badoux, X. Celgene - Future Leaders in Hematology Award for significant contributions in the field of hematology. 2011.
For further information contact:

CLINICAL TRIALS UNIT
Roslyn Ristuccia        9113 2977

Ground Floor W R Pitney Clinical Sciences Building
The St George Hospital
Gray Street KOGARAH NSW 2217 AUSTRALIA
Phone:   (612) 9113 1935
Fax:     (612) 9113 2960
End.